ArcDia International Ltd.

ArcDia addresses healthcare’s largest problems with its rapid infectious disease diagnostics platform. Based in Finland, ArcDia is an ISO 13485 certified company whose proprietary TPX technology has been awarded by Frost & Sullivan, and whose sister technology won The Nobel Prize in Chemistry in 2014.

ArcDia’s mariAST® is the most promising platform to tackle antibiotic resistance, a growing concern that directly causes 23,000 deaths every year in the US alone, and can soon make many routine operations too risky to perform.

Since 2011, ArcDia’s mariPOC® has been in use for rapid detection of respiratory and gastrointestinal infectious diseases. It is a near-patient technology with ease-of-use, cost-efficiency, high performance and accuracy. mariPOC® test system is IVD CE marked for respiratory tract infections, pharyngitis and gastrointestinal infection testing. mariPOC® is the market leader in Finland in respiratory infection testing with nationwide installation base.

The mariAST® and mariPOC® platforms are based on the proprietary and Nature published ArcDia™ TPX detection technology. The TPX technology allows multianalyte rapid testing with fully automated and random-access test system. The platform is available for clinical diagnostic use, R&D, licensing and distribution.

ArcDia is already distributing to numerous countries but also seeks new partners.